PharmEasy parent trims FY26 loss to Rs 520 crore on shift to high-margin businesses

API Holdings, the parent of healthtech startup PharmEasy, narrowed its consolidated net loss by 67% to Rs 520 crore in the year ended March 2026 from Rs 1,572 crore in the previous fiscal year, according to its annual report . In FY26, the company shifted towards higher-margin businesses, including diagnostics, hospital management systems, pathology laboratories and generic pharmaceuticals, which delivered better EBITDA margins. Revenue from operations rose 13% to Rs 6,619 crore, compared with R